CompuMed debuted its digital OsteoView 2000 bone densitometry scanner at the annual meeting of the American Society of Bone and Mineral Research held last week. OsteoView 2000 will allow diagnosis of both osteoporosis and arthritis, according to the
CompuMed debuted its digital OsteoView 2000 bone densitometry scanner at the annual meeting of the American Society of Bone and Mineral Research held last week. OsteoView 2000 will allow diagnosis of both osteoporosis and arthritis, according to the Manhattan Beach, CA-based company.
The scanner leverages off a set of image processing and segmentation tools developed by CompuMed, as well as direct digital x-ray capture technology developed by Varian Associates and Xerox under a grant from the U.S. Defense Advanced Research Projects Agency (DARPA). CompuMed has received exclusive rights to the technology in the fields of appendicular bone mass measurement and automated arthritis detection, according to CompuMed. Clinical trials will begin in October for OsteoView 2000, and the company expects to receive Food and Drug Administration 510(k) clearance in 1998.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.